Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

N/ACompletedNCT05205226

Hunan Province Tumor Hospital636 enrolled

Overview

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

Study Type

OBSERVATIONAL

Enrollment

636

Conditions

Non Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy Exclusion Criteria: * EGFR/ALK/ROS1 driver gene mutation * Chemotherapy only * Concurrent radio-chemotherapy * Surgery * Single-agent immunotherapy * No treatment information available

Locations (1)

Hunan Cancer Hospital

Changsha, Hunan, China

Outcomes

Primary Outcomes

PFS

Progression free survival time

Time frame: January 2018 to June 2021

Secondary Outcomes

radiotherapy control time

Time frame: January 2018 to June 2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.